This comprehensive analysis exposes the deep-rooted corruption within Western pharmaceutical corporations and their regulatory apparatus. While the United States provides the most extensively documented cases due to its disclosure laws and court records, the pattern of corporate misconduct spans North America, Europe, and Australia.
Drawing from a 2014 Princeton University study by political scientists Martin Gilens and Benjamin Page, which found that the preferences of average Americans have "a statistically non-significant impact" on public policy while economic elites and organised business interests enjoy disproportionate influence, this investigation reveals how Big Pharma has systematically captured regulatory agencies, silenced critics, and prioritised profits over public health across the Western world.
Through massive lobbying expenditures exceeding $6 billion since 1999, industry-funded regulatory oversight where pharmaceutical companies pay over 75% of the FDA's drug evaluation budget, and a revolving door between agencies and corporations, the pharmaceutical industry operates with virtual impunity despite billions in criminal settlements for fraud, bribery, and deception.
The U.S. political system is widely recognised as deeply influenced by entrenched wealth and corporate power. Similar dynamics exist across Western democracies.
The U.S. political system is widely recognised as deeply influenced by entrenched wealth and corporate power. A seminal 2014 study by political scientists Martin Gilens and Benjamin Page at Princeton University found that the preferences of average Americans have "a statistically non-significant impact" on public policy, while economic elites and organised business interests enjoy disproportionate influence. Similar dynamics exist across Western democracies.
Gilens & Page Study β Cambridge University Press
Big Pharma spends more on lobbying than any other industry. In the US alone, from 1999 to 2022, pharmaceutical and health product companies spent over $6 billion lobbying Congress. Similar lobbying dominates European institutions and national parliaments.
OpenSecrets: Pharma Industry Lobbying
One of the most alarming aspects of pharmaceutical regulation is the deep financial entanglement between government drug agencies β the FDA and CDC in the US, the EMA in Europe, and the TGA in Australia β and the very industry they are supposed to regulate.
The CDC also receives millions in "grants" and "partnership funds" from pharmaceutical companies, especially through its CDC Foundation. From fiscal years 2014 to 2018, it received $79.6 million from companies like Pfizer, Biogen, and Merck, and $161 million from corporations since its inception in 1995.
Because regulators often rely on industry-submitted data for drug approval, pharmaceutical companies essentially fund and conduct their own safety and efficacy trials. Independent replication is rare, and raw trial data is frequently withheld from public view.
This creates a dangerous feedback loop:
JAMA: Transparency of Clinical Trial Data
Former regulatory officials routinely take lucrative positions in pharmaceutical companies, and executives move into regulatory roles. This erodes regulatory integrity globally.
| Name | Role in Government | Industry Position |
|---|---|---|
| Scott Gottlieb | FDA Commissioner | Pfizer Board of Directors |
| Julie Gerberding | CDC Director | Merck Vaccine Division President |
| Stephen Hahn | FDA Commissioner | Flagship Pioneering (funds Moderna) |
| Patrick Vallance | UK Chief Scientific Adviser | Former GSK R&D President |
| Janet Woodcock | FDA Official | Acting FDA Commissioner (after opioid approvals) |
| Daniel Troy | FDA Chief Counsel | SVP & General Counsel at GSK |
| Elizabeth Fowler | Johnson & Johnson Executive | Director of CMS Innovation Center |
Stat News (Gottlieb) | Reuters (Gerberding) | STAT News (Hahn)
The following is an index of documented criminal convictions, guilty pleas, and major civil settlements by Western pharmaceutical companies. All figures are verified from official government and legal sources.
| Company | Offense | Penalty | Year |
|---|---|---|---|
| Purdue Pharma | Misleading OxyContin marketing | $8.3B | 2020 |
| Johnson & Johnson | Opioid crisis, talc cancer, off-label drugs | $5B+ | Multiple |
| GlaxoSmithKline | Off-label promotion, data concealment | $3B | 2012 |
| Pfizer | Off-label promotion, kickbacks | $2.3B | 2009 |
| Johnson & Johnson | Risperdal off-label to elderly/children | $2.2B | 2013 |
| Abbott Laboratories | Depakote off-label to children | $1.5B | 2012 |
| Eli Lilly | Zyprexa off-label to elderly | $1.4B | 2009 |
| Merck & Co. | Vioxx misbranding | $950M | 2011 |
| Novartis | Doctor kickbacks | $642M | 2020 |
| Bristol-Myers Squibb | Illegal marketing, fraudulent pricing | $515M | 2007 |
| Cephalon | Off-label marketing | $425M | 2008 |
| Biogen | Illegal kickbacks to physicians | $900M | 2022 |
Sources: DOJ Pfizer (2009); DOJ GSK (2012); DOJ J&J (2013); DOJ Biogen (2022)
| Company | Country | Offense | Penalty | Year |
|---|---|---|---|---|
| AstraZeneca | UK/Sweden | Illegal Seroquel promotion | $520M | 2010 |
| Eli Lilly | US/Europe | Zyprexa off-label | $1.4B | 2009 |
| Novartis AG | Switzerland | Doctor kickbacks | $642M | 2020 |
| Actelion Pharmaceuticals | Switzerland | Medicare fraud | $360M | 2018 |
| Company | Offense | Company Penalty | Executive Sentence |
|---|---|---|---|
| Alkaloids of Australia | Criminal price-fixing cartel | $2M | 32 months prison |
ACCC Criminal Sentencing Announcement
Pharmaceutical giants Eli Lilly, Sanofi, and Novo Nordisk were sued for allegedly conspiring to inflate insulin prices by over 1,000%.
J&J faces extensive litigation alleging talc products contained asbestos and caused ovarian cancer and mesothelioma. Internal documents show J&J scientists expressed concerns about contamination since the 1970s. A $2.1 billion award was made to 22 women in Missouri (2020), later reduced on appeal. As of 2023, over 38,000 lawsuits are pending. J&J's attempt to resolve claims through a subsidiary's bankruptcy filing was rejected by a federal judge.
Reuters: Talc Verdict | Reuters: 38,000 Lawsuits
From the 1990s through 2016, Johnson & Johnson cultivated and processed opium poppy plants, becoming the top US supplier of active opioid ingredients for manufacturers including Purdue Pharma. A Washington Post investigation revealed that J&J subsidiaries engineered a "super poppy" in Tasmania and became the leading maker of narcotics for opioid pills. Their U.S. subsidiary, Noramco, processed these materials into oxycodone and hydrocodone, capturing half or more of the U.S. market.
WA AG Announcement | Washington Post: J&J Opium Supply
J&J illegally marketed antipsychotic drugs Risperdal, Invega, and Natrecor for unapproved uses β including treating elderly dementia patients and children β despite known risks of stroke and diabetes. Janssen pleaded guilty to a criminal misdemeanor. The $2.2 billion settlement included a $485 million criminal fine, a $1.72 billion civil settlement, and a Corporate Integrity Agreement imposing ongoing government oversight.
A March 2024 study in the BMJ found women using Depo-Provera for at least one year are 5 times more likely to develop meningiomas, with European studies showing up to 20 times higher risk for long-term users. France implemented strict restrictions in 2021. Multiple lawsuits allege Pfizer failed to warn about this risk. Despite the evidence, Pfizer has not updated the US warning label to include brain tumour risks.
BMJ Study on Meningioma Risk | The Guardian
Pfizer pleaded guilty to criminal misbranding of Bextra and paid $2.3 billion β the largest healthcare fraud settlement in US history at the time. Pfizer subsidiary Pharmacia & Upjohn entered a criminal felony plea. This followed a prior 2004 settlement for Neurontin off-label promotion. Additionally, Pfizer (via its subsidiary Biohaven) paid $60M to resolve allegations of kickbacks to doctors to prescribe migraine drug Nurtec ODT.
DOJ Pfizer Guilty Plea (2009) | DOJ Biohaven Kickbacks
| Company | Offense | Penalty | Year |
|---|---|---|---|
| Bristol-Myers Squibb | Illegal marketing, fraudulent pricing for multiple drugs including Abilify | $515M | 2007 |
| Cephalon Inc. | Off-label marketing of Actiq, Gabitril, and Provigil | $425M | 2008 |
| Biogen Inc. | Illegal kickbacks to physicians to prescribe multiple sclerosis drugs | $900M | 2022 |
| Martin Shkreli / Turing | Daraprim price hike ($13.50 β $750) | 5,500% increase | 2015 |
| Mylan | EpiPen price hike (despite taxpayer subsidies) | 500%+ increase | 2016 |
| Gilead | Remdesivir pricing (publicly-funded drug) | $3,000+ per course | 2020 |
DOJ Biogen | NPR EpiPen | Stat News Remdesivir
The period from 2001 to 2024 shows escalating financial penalties and increasing violation frequency. Both fines and violations peaked around 2012, with multiple concurrent enforcement actions. Companies with prior violations continued offending, demonstrating that penalties function as operational costs rather than deterrents.
| Metric | Figure |
|---|---|
| Largest Healthcare Fraud Settlement | $3B (GSK, 2012) |
| Opioid Deaths in the US (1999β2020) | 90,000+ |
| Companies with $1B+ Penalties | 15+ |
| Total Pharmaceutical Criminal Settlements Since 2000 | $50B+ |
While most pharmaceutical cases result in corporate fines, rare cases have seen executive prison sentences:
The pharmaceutical industry consistently maintains the highest profit margins of any major industry globally, averaging 30β42% compared to 4β8% for most other sectors.
| Industry | Average Profit Margin |
|---|---|
| Pharmaceuticals | 30β42% |
| Technology | 15β25% |
| Oil & Gas | 5β15% |
| Banking | 8β12% |
| Retail | 2β6% |
| Manufacturing | 4β8% |
| Company | 2022 Revenue | 2022 Net Profit | Profit Margin |
|---|---|---|---|
| Pfizer | $100.3B | $31.4B | 31.3% |
| Johnson & Johnson | $94.9B | $20.9B | 22.0% |
| AbbVie | $58.1B | $23.7B | 40.8% |
| Merck | $59.3B | $14.5B | 24.4% |
| Novartis | $50.5B | $8.7B | 17.2% |
Sources: Company annual reports (10-K filings), SEC databases.
Even the largest criminal settlements represent a tiny fraction of pharmaceutical profits β typically 2β7% of annual revenue.
| Company | Fine | Year | Revenue (Fine Year) | Fine as % of Revenue | Days to "Earn Back" |
|---|---|---|---|---|---|
| Pfizer | $2.3B | 2009 | $45B | 5.1% | 18 days |
| GSK | $3.0B | 2012 | $41.5B | 7.2% | 26 days |
| Johnson & Johnson | $2.2B | 2013 | $71.3B | 3.1% | 11 days |
| Novartis | $678M | 2020 | $48.7B | 1.4% | 5 days |
Internal documents revealed in lawsuits show that companies explicitly calculate potential fines as "cost of doing business":
The pharmaceutical industry spends billions annually on advertising, which not only shapes public policy but heavily influences what the public sees through mainstream media and search engines.
BMJ (GΓΈtzsche) | Wall Street Journal
Major medical journals have become financially dependent on pharmaceutical advertising revenue, creating conflicts of interest that compromise editorial independence. Journals that publish studies critical of pharmaceutical products risk losing millions in advertising dollars. This creates systematic bias toward publishing industry-favorable research while suppressing or rejecting studies that threaten pharmaceutical profits.
Corruption extends all the way down the hierarchy to individual doctors. Payments framed as "consulting fees" or "speaking engagements" create conflicts of interest that influence prescribing habits.
U.S. CMS Open Payments Database
Rep. Burton: Mr. Egan, has Thimerosal ever been tested by a health agency?
Dr. Egan: Aaahβ¦Its been early, in the world, those early tests that you know of, uhβ¦ that were done by, ahhhhβ¦ Eli Lily.
Rep. Burton: And when was that tested?
Dr. Egan: It was done in 1929.
Rep. Burton: ...they tested this on 27 people who were dying of meningitis. And all of them died of meningitis. And so they said, there was no correlation between their deaths, and the mercury in the vaccines. That is the only test that has ever been done on Thimerosal, that I know of. Do you know any other?
Dr. Egan: No, in people, no.
Below is footage of FDA Director William Egan testifying about the period when mercury was introduced into vaccines. He admits under oath that hardly any safety testing was performed.
This case exposes a fundamental violation of ethical and legal principles:
| How It Should Work | How It Actually Worked |
|---|---|
| Manufacturer proves safety via rigorous, modern toxicology studies. | Manufacturer uses it for decades without adequate human safety trials. |
| Regulator reviews data before public use. | Regulator waits for public outcry to review data after decades of use. |
| If uncertain, do not approve. | If uncertain, allow it until proven otherwise. |
The FDA failed the public by reversing the burden of proof. When Dr. Egan admitted the only human data came from 1929, he was essentially confessing that the agency had been operating on blind faith for generations.
Thimerosal was removed as a precautionary measure in 1999, not because it was proven unsafe. The removal was driven by the "precautionary principle" β to minimise total mercury exposure in infants, even without evidence of harm.
This creates a paradox: if thimerosal required removal as a precaution despite no evidence of harm, then logically it could only be reinstated if proven absolutely safe beyond any doubt β an impossible standard no chemical could meet.
The agencies have painted themselves into a corner: they removed it as a precaution, then spent decades proving it was safe, but can never put it back because it's no longer necessary, the public wouldn't trust it, and the political cost is too high.
A 2024 meta-analysis of 75,000 studies across biomedical sciences concluded that results from as many as one in seven may have been at least partially faked. More than half of researchers admitted to being unable to replicate their own experiments.
Recent investigations have uncovered organised crime networks operating within scientific publishing. Flagged editors handled 1.3% of papers but nearly one-third of all retracted papers. Of the 79 papers that one editor had handled at PLOS ONE, 49 have been retracted.
Wiley and Hindawi have retracted around 8,000 articles in the past year. As many as 19 Hindawi journals were delisted after investigations revealed widespread fraud.
Pharmaceutical companies routinely hire professional writing companies to produce research papers, then pay prestigious academic researchers to put their names on these ghostwritten publications. This practice allows companies to launder corporate marketing materials as independent academic research.
CDC Autism Prevalence Data β cdc.gov | Historical Autism Rates Study β PubMed | CDC 2023 ADDM Report β cdc.gov
To understand autism's dramatic rise, you have to understand what happened to government regulation of corporations over the same period. Beginning in the late 1970s and accelerating sharply through the 1980s and 1990s, Western governments β led by the US and UK β adopted a philosophy of deregulation: reducing oversight of industry, removing requirements for safety testing before market entry, and replacing precautionary rules with a system where chemicals and products are treated as safe unless proven otherwise, often after the damage is already done.
Under this framework, corporations are not required to prove a substance is safe before releasing it into the food supply, the water supply, children's products, pesticides, or medicines. The burden falls on regulators and the public to prove harm β a process that takes decades, requires enormous resources, and is routinely obstructed by industry lobbying. By the time a toxin is confirmed harmful, an entire generation has been exposed.
This is not an accident. It is the direct result of corporations lobbying governments to be allowed to skip safety testing β because safety testing is expensive and slows down profit. Deregulation is not an abstract policy debate. Its consequences show up in children's brains.
Autism research increasingly points toward a model where multiple environmental toxins, acting during sensitive periods of brain development, disrupt normal neurological development. None of these toxins were adequately tested for neurodevelopmental effects before widespread human exposure. Each was allowed into widespread use because corporations successfully lobbied against safety requirements.
Mercury is one of the most potent neurotoxins known to science. Ethylmercury β the form used in thimerosal, the preservative added to multi-dose vaccine vials β was never subject to adequate safety testing before being injected into infants and children at scale. FDA Director William Egan admitted under oath that minimal safety testing was conducted before thimerosal was widely used in childhood vaccines. The decision was made largely for manufacturing convenience and cost reduction β not on the basis of demonstrated safety.
The expanded vaccination schedule of the 1990s dramatically increased the cumulative mercury dose young children received in their first two years of life, coinciding with the beginning of the steep rise in autism diagnoses. Thimerosal was quietly removed from routine childhood vaccines in the early 2000s β not because it was proven safe, but as a "precautionary measure." That phrase is an admission. You do not take a precautionary measure over something you are confident is harmless.
NIH: Thimerosal and Neurodevelopment | PubMed: Mercury Exposure in Infants
Aluminium salts are used as adjuvants in many vaccines β substances that amplify the immune response. Like thimerosal, aluminium adjuvants were introduced into vaccines and assumed safe without systematic neurodevelopmental safety testing. Aluminium is a known neurotoxin at sufficient doses, and its effects on the developing infant brain have been inadequately studied.
Research by immunologist Dr. Christopher Exley and others has found that aluminium accumulates in brain tissue and has been detected in unusually high concentrations in post-mortem brain tissue of people with autism. The mechanism β by which vaccine-injected aluminium nanoparticles may be transported by immune cells to the brain β has been described in peer-reviewed literature, though the full picture is still being established. The regulatory justification is the same used for thimerosal, asbestos, and leaded petrol: decades of use without apparent acute harm.
Exley et al.: Aluminium in Autistic Brain Tissue | PubMed: Aluminium Adjuvant Toxicokinetics
Glyphosate β the active ingredient in Roundup, manufactured by Monsanto (now Bayer) β is the most widely used herbicide in the world. Its use exploded after the introduction of genetically modified "Roundup Ready" crops in the mid-1990s. Glyphosate residues are now detectable in most Western food supplies, in drinking water, and in human urine. Research has linked glyphosate exposure to disruption of the gut microbiome, which plays a significant role in neurodevelopment and immune function. Glyphosate was classified as a "probable human carcinogen" by the WHO's IARC in 2015 β yet it remains in widespread use, and Bayer has paid billions in settlements for cancer cases linked to Roundup while continuing to sell the product.
More broadly, organophosphate pesticides are well-established neurotoxins. A 2014 study in Environmental Health Perspectives found that living within one mile of agricultural pesticide application was associated with a 60β70% increased risk of autism in offspring.
WHO IARC: Glyphosate Classification | EHP: Pesticide Exposure and Autism | Seneff et al.: Glyphosate, Gut Microbiota, and Autism
The link between air pollution and autism is now one of the most robust findings in environmental health research. Multiple large-scale epidemiological studies across the US, Europe, and Asia have found that children exposed to higher levels of traffic-related air pollution β particularly fine particulate matter (PM2.5) and nitrogen dioxide (NO2) β during pregnancy and early childhood have significantly elevated autism risk. A 2013 Harvard School of Public Health study found that women in the highest quartile of particulate matter exposure during pregnancy were twice as likely to have a child with autism. Air pollution particles cross the blood-brain barrier and placental barrier, cause neuroinflammation, and disrupt brain development at critical windows.
Harvard/HSPH: Air Pollution and Autism (EHP, 2013) | PubMed: Traffic-related Air Pollution and ASD
PFAS ("forever chemicals") are a class of thousands of industrial chemicals used in non-stick cookware, food packaging, clothing, and firefighting foam. They do not break down in the environment or the human body and are now detectable in the blood of virtually every person on Earth. PFAS are endocrine disruptors linked to immune dysfunction, thyroid disease, developmental disorders, and cancer. Thyroid disruption during pregnancy is particularly concerning, as thyroid hormone is critical for brain development. Polybrominated diphenyl ethers (PBDEs) β flame retardants used in furniture, electronics, and children's products since the 1970s β are another class of persistent neurotoxic chemicals linked to lower IQ, attention problems, and autism-like behaviours. The chemical industry lobbied for decades to prevent their regulation.
NIH: PFAS and Neurodevelopment | EHP: PBDE Exposure and Autism
Phthalates and BPA are chemicals used to make plastics flexible and hard respectively, found in food containers, water bottles, toys, medical equipment, and tin can linings. Both are endocrine disruptors that mimic hormones, particularly oestrogen, and interfere with hormonal signalling. Prenatal phthalate exposure has been associated in multiple studies with lower IQ, attention deficit disorders, and autism spectrum traits. BPA has been shown to disrupt foetal brain development at very low doses in animal models. The chemical industry successfully lobbied for decades to prevent meaningful regulation β BPA was eventually restricted in baby bottles in many countries, but only after years of lobbying delays, and only in one product category.
PubMed: Prenatal Phthalate Exposure and Autism Traits | NIH: BPA and Neurodevelopment
Each of the toxins described above shares a common history:
This is not the story of a few bad actors. It is the story of a system β a regulatory philosophy that places the burden of proof on the public rather than on the corporation, that treats profit as a higher priority than the precautionary protection of children's developing brains. The autism epidemic is, on its most fundamental level, the human cost of deregulation. The solution is not just better vaccines or cleaner pesticides β it is a fundamental restructuring of the relationship between government and industry, restoring the precautionary principle: corporations must prove safety before exposing the public to their products, not after.
Since late 2020, as COVID-19 vaccines rolled out globally, many countries have reported significant and sustained excess mortality that can't be fully explained by COVID-19 deaths alone. According to WHO, global excess mortality reached 14.9 million for 2020-2021 alone. In numerous Western nations, all-cause mortality has remained elevated between 10-20% above pre-pandemic baselines for multiple consecutive years β a sustained demographic anomaly not seen since World War II.
Japan Study (2025) β JMA Journal (PMID: 40416011)
Japan recorded the world's highest mRNA vaccination rate (3.6 doses/capita). Excess deaths per million exceeded 1,400 in 2023 β three times higher than the United States. Crucially, COVID-19 deaths accounted for only 10% of these excess deaths. The authors explicitly state that "sufficient studies and data disclosures have not been conducted to adequately investigate the possible contribution of mRNA vaccines" to this phenomenon.
Kakeya H, Nitta T, Kamijima Y, Miyazawa T. JMA Journal. 2025;8(2):584-586. doi:10.31662/jmaj.2024-0298
Japan Age-Specific Analysis (2026) β Frontiers in Public Health (PMID: 42088235)
A follow-up study by Iwamoto et al. examined age-specific patterns of all-cause mortality across COVID-19 booster dose groups in two Japanese municipalities (Hamamatsu 2021β2024, Matsudo 2021β2025). Among individuals aged 20β49 years, all-cause mortality rates were higher among those who had received β₯5 doses than among those who had received fewer doses. Among those aged 50β64, mortality was higher among those with 6 doses than 1, 3, or 4 doses. This demonstrates a large effect size in younger, lower-baseline-risk populations β precisely where a safety signal is most concerning.
Iwamoto Y, Kusunoki H, Kamijima Y, et al. Front Public Health. 2026;14:1795437. doi:10.3389/fpubh.2026.1795437
Australian Bradford Hill Analysis (2023)
Australian official mortality data show no significant excess deaths in 2020 (pre-vaccine). Excess mortality became significant only in 2021, when vaccination began. Excess mortality was strongly correlated (+74%) with COVID-19 mass injections five months earlier.
Sy W. J Clin Exp Immunol. 2023;8(2):542-556.
Australian Ecological Study (2026)
In 4 of Australia's 8 major regions, excess mortality correlated with "rapid and thorough COVID-19 vaccination programs, before mass exposure to COVID-19, and in the absence of lengthy lockdowns." The author concludes it is a "near-certainty that COVID-19 vaccines have beenβand continue to beβcontributing to excess mortality."
Lataster R. Int J Risk Saf Med. 2026.
31 European Countries Study (2023) β Western Norway University
Aarstad & Kvitastein examined the relationship between vaccination uptake by end of 2021 and all-cause mortality in the first nine months of 2022 across 31 European countries. They found a statistically significant correlation: for every one percentage-point increase in vaccination uptake, there was an associated 0.105% monthly increase in excess mortality (95% CI, 0.075β0.134; p < 0.001).
Aarstad J, Kvitastein OA. Preprints. 2023. doi:10.20944/preprints202302.0350.v1
Autopsy Systematic Review (2024) β ESC Heart Failure
The largest autopsy-based study reviewed 1,691 studies and included 28 autopsy cases. Three independent cardiac pathologists assessed each case. The review found "internal and external consistency seen among cases in this review with known COVID-19 vaccine-induced myocarditis, its pathobiological mechanisms, and related excess death." All 28 deaths were "most likely causally linked" to vaccination.
Hulscher N, Hodkinson R, Makis W, McCullough PA. ESC Heart Failure. 2024;12(5):3212-3225. PMID: 38221509.
Circulation Review (2021) β American Heart Association (PMID: 34281357)
Published in the AHA's flagship journal, Bozkurt et al. confirmed that myocarditis is "a rare complication of COVID-19 mRNA vaccinations, especially in young adult and adolescent males", with highest risk after the second dose. This finding has been replicated across multiple countries and health systems, establishing strong consistency.
Bozkurt B, Kamat I, Hotez PJ. Circulation. 2021;144(6):471-484. doi:10.1161/CIRCULATIONAHA.121.056135
Israel Nationwide Study (2021) β New England Journal of Medicine (PMID: 34614329)
Witberg et al. conducted a large population-based study of over 2.5 million vaccinated members of Clalit Health Services in Israel. They found the highest incidence of myocarditis β 10.69 cases per 100,000 β in male patients aged 16β29 years. The study confirmed that myocarditis after mRNA vaccination is a consistent finding across age and sex groups, with the strongest signal in young males after the second dose.
Witberg G, Barda N, Hoss S, et al. N Engl J Med. 2021;385(23):2132-2139. doi:10.1056/NEJMoa2110737
European Parliament Acknowledgment (2024)
A parliamentary question referenced this autopsy study as providing "robust evidence that COVID-19 vaccines can be linked to death" and noted that "the consistency seen among cases in this review" supports causality.
European Parliament. E-002597/2024.
UK Young People Study (2024)
Studying cohorts aged 12-29 in England, researchers found that deaths increased significantly (95% CIs) in 10 of 11 weeks after COVID-19 vaccination compared to the first week. In three of those weeks, deaths doubled.
PMC. 2024.
Mimura W, Ishiguro C, et al. Human Vaccines & Immunotherapeutics. 2024;20(1):2350091.
"Fatal arrhythmia in a young man after COVID-19 vaccination: An autopsy report." Medicine. 2024.
| Criterion | Key Study | Key Finding |
|---|---|---|
| Strength | Kakeya et al. (JMAJ, 2025; PMID: 40416011); Iwamoto et al. (Front Public Health, 2026; PMID: 42088235) | Japan: 1,400+ excess deaths/million, 3Γ US rate; only 10% attributed to COVID-19. Age 20β49: β₯5 doses associated with higher mortality than fewer doses. Age 50β64: 6 doses higher than 1, 3, or 4 doses. |
| Strength | Sy W. (J Clin Exp Immunol, 2023) | Australia: +74% correlation with injections 5 months prior |
| Strength | Aarstad & Kvitastein (Preprints, 2023) | 31 European countries: 0.105% monthly excess mortality increase per 1% vaccination uptake (p < 0.001) |
| Consistency | Hulscher et al. (ESC Heart Failure, 2024; PMID: 38221509) | Systematic review of 28 autopsy cases, all "most likely causally linked" to vaccination; mean age 44.4 years; cardiovascular system only organ affected in 26/28 cases |
| Consistency | UK young people study (2024) | Deaths increased in 10/11 weeks post-vaccination; doubled in 3 weeks |
| Consistency | Bozkurt et al. (Circulation, 2021; PMID: 34281357) | Myocarditis recognized as rare complication of mRNA vaccines, especially in young adult and adolescent males β replicated across multiple countries |
| Consistency | Witberg et al. (NEJM, 2021; PMID: 34614329) | 2.5M vaccinated Israelis: 10.69 myocarditis cases per 100,000 in males 16β29; highest risk after second dose β replicated across large health system |
| Specificity | Kakeya et al. (JMAJ, 2025) | 90% of Japan's excess deaths not attributed to COVID-19 |
| Specificity | Sy W. (2023) | No excess deaths in Australia in 2020; excess began in 2021 |
| Specificity | Hulscher et al. (ESC Heart Failure, 2024) | Cardiovascular system was the only organ system affected in 26 of 28 autopsy cases β a specific pathological signature |
| Temporality | Hulscher et al. (ESC Heart Failure, 2024) | Mean 6.2 days from vaccination to death; median 3 days |
| Temporality | Sy W. (2023) | 5-month lag between injections and excess mortality |
| Temporality | Morgan et al. (World J Cardiol, 2022; PMID: 36161056) | Myocarditis typically presents within one week of receiving the second dose of mRNA vaccination |
| Temporality | Witberg et al. (NEJM, 2021; PMID: 34614329) | Myocarditis cases presented median 2β3 days after second dose; 76% mild, 22% intermediate, 1 cardiogenic shock |
| Temporality | Iwamoto et al. (Front Public Health, 2026; PMID: 42088235) | Clear temporal clustering of deaths within days to weeks of each booster dose across all age groups in Japanese municipal data |
| Dose-Response | Kakeya et al. (JMAJ, 2025); Iwamoto et al. (2026) | Highest mRNA dose rate = highest excess mortality; age 20β49: β₯5 doses higher mortality; age 50β64: 6 doses higher than 1, 3, or 4 doses |
| Dose-Response | DlouhΓ½ et al. (Vaccine, 2026; PMID: 41905062) | Transient elevation of NT-proBNP after mRNA vaccination, particularly after second dose β biomarker evidence of cardiac strain |
| Plausibility | Hulscher et al. (ESC Heart Failure, 2024) | Autopsy-confirmed myocarditis; pathobiological mechanisms established including spike protein in cardiac tissue |
| Plausibility | Seneff et al. (Food Chem Toxicol, 2022; PMID: 35436552) | MIT-published mechanism: mRNA vaccines induce profound impairment in type I interferon signaling; exosomes containing spike protein and microRNAs travel to distant sites including cardiac tissue |
| Plausibility | Won et al. (Front Immunol, 2022; PMID: 35251049) | Johns Hopkins: Increased IL-18-dependent immune responses associated with myopericarditis after mRNA vaccination; IL-18 administration in mice caused cardiac dysfunction |
| Plausibility | DlouhΓ½ et al. (Vaccine, 2026; PMID: 41905062) | Charles University: 49% of 83 healthy adults showed NT-proBNP elevation >1.5Γ baseline after second dose β biomarker evidence of subclinical myocardial stress |
| Coherence | Kakeya et al. (JMAJ, 2025) | Japan's exclusive mRNA use coherent with observed excess |
| Coherence | Tuvali et al. (J Clin Med, 2022) | No statistically significant increase in myocarditis after COVID-19 infection in unvaccinated β contrast with vaccine-associated myocarditis |
| Experiment | Kakeya et al. (JMAJ, 2025); Iwamoto et al. (2026) | Japan as natural experiment: low COVID deaths, high vaccine rate, high excess; age-specific booster dose group analysis |
| Experiment | Hulscher et al. (ESC Heart Failure, 2024) | Autopsy as direct "experiment": post-mortem analysis examines causal pathway directly |
| Analogy | Historical | Thimerosal, tobacco, regulatory capture patterns |
Chalmers University Study (2023)
"Excess Mortality and the Effect of the Covid-19 Vaccines: Update on the European Data" investigated the relationship across 28 EU/EES countries. Since April 2022, excess mortality and vaccination rates have been consistently positively correlated.
Chalmers University. 2023.
UK ONS Data Analysis (2024)
"Across all age groups, all-cause mortality SMRs increased from a certain date, dependent on the age group." EuroMoMo recorded 328,047 excess deaths in 2022 and 305,301 in 2021 in Europe.
F1000Research. 2024.
European Active Populations Study (2023)
Investigated whether "Covid-19 vaccination campaigns could have had an immediate negative impact on excess deaths continues to be debated two years later, in particular in the less than 45 years old."
ICCBB 2023.
Hulscher et al. β Systematic Autopsy Review (ESC Heart Failure, 2024; PMID: 38221509)
Published in the European Society of Cardiology's official journal, this systematic review of 28 autopsy cases found all 28 deaths were "most likely causally linked to COVID-19 vaccination". Mean age: 44.4 years. Mean time from vaccination to death: 6.2 days. The cardiovascular system was the only organ system affected in 26 of 28 cases. The authors explicitly applied the Bradford Hill criteria and concluded there is "a high likelihood of a causal link between COVID-19 vaccines and death from myocarditis."
Hulscher N, Hodkinson R, Makis W, McCullough PA. ESC Heart Failure. 2024;12(5):3212-3225. doi:10.1002/ehf2.14680
Seneff et al. β Molecular Mechanism (Food and Chemical Toxicology, 2022; PMID: 35436552)
Published by MIT researcher Stephanie Seneff in a peer-reviewed Elsevier journal, this paper identifies a plausible biological mechanism: mRNA vaccines induce "a profound impairment in type I interferon signaling" and release exosomes containing spike protein and microRNAs that travel to distant sites including cardiac tissue. The paper links this to myocarditis, neurodegenerative disease, impaired adaptive immunity, and tumorigenesis.
Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Food Chem Toxicol. 2022;164:113008. doi:10.1016/j.fct.2022.113008
Bozkurt et al. β Myocarditis Review (Circulation, 2021; PMID: 34281357)
Published in the American Heart Association's flagship journal, this review confirmed that myocarditis is "a rare complication of COVID-19 mRNA vaccinations, especially in young adult and adolescent males", with highest risk after the second dose. This established the consistency and specificity of the finding across multiple populations.
Bozkurt B, Kamat I, Hotez PJ. Circulation. 2021;144(6):471-484. doi:10.1161/CIRCULATIONAHA.121.056135
Iwamoto et al. β Japan Age-Specific Mortality (Front Public Health, 2026; PMID: 42088235)
This follow-up study by Kakeya's group examined age-specific patterns of all-cause mortality across COVID-19 booster dose groups in two Japanese municipalities. It found age-specific differences in all-cause mortality rates across booster dose groups, providing further evidence of a dose-response relationship and strengthening the specificity of the Japan natural experiment.
Iwamoto Y, Kusunoki H, Kamijima Y, et al. Front Public Health. 2026;14:1795437. doi:10.3389/fpubh.2026.1795437
DlouhΓ½ et al. β Cardiac Biomarker Evidence (Vaccine, 2026; PMID: 41905062)
This longitudinal biomarker study found transient elevation of NT-proBNP (a marker of cardiac strain) after mRNA COVID-19 vaccination, particularly after the second dose. This provides biomarker-level evidence supporting the plausibility of cardiac damage from vaccination, even in healthy adults.
DlouhΓ½ P, PetrΓ‘Ε‘ M, LesnΓ‘ IK, et al. Vaccine. 2026;80:128535. doi:10.1016/j.vaccine.2026.128535
Won et al. β Immune Mechanism of Myopericarditis (Front Immunol, 2022; PMID: 35251049)
This study identified increased IL-18-dependent immune responses associated with myopericarditis after mRNA COVID-19 vaccination, providing a specific immunological mechanism linking vaccination to cardiac inflammation.
Won T, Gilotra NA, Wood MK, et al. Front Immunol. 2022;13:851620. doi:10.3389/fimmu.2022.851620
Witberg et al. β Myocarditis in a Large Israeli Cohort (NEJM, 2021; PMID: 34614329)
This population-based study of over 2.5 million vaccinated members of Clalit Health Services in Israel found 54 confirmed myocarditis cases. The estimated incidence was 2.13 cases per 100,000 persons who had received at least one dose, rising to 10.69 per 100,000 in males aged 16β29. Most cases (76%) were mild, but 22% were intermediate and 1 case involved cardiogenic shock. Of 14 patients with left ventricular dysfunction on admission, 10 still had dysfunction at discharge. This large-cohort study from a major health system independently confirmed the myocarditis signal.
Witberg G, Barda N, Hoss S, et al. N Engl J Med. 2021;385(23):2132-2139. doi:10.1056/NEJMoa2110737
Kakeya et al. β Japan Excess Deaths (JMA Journal, 2025; PMID: 40416011)
Published in the Japan Medical Association Journal, this study documented that Japan β with the world's highest mRNA vaccination rate β experienced a "significant increase in excess deaths" in 2022 and 2023. The authors note that "sufficient studies and data disclosures have not been conducted to adequately investigate the possible contribution of mRNA vaccines" and call for urgent investigation.
Kakeya H, Nitta T, Kamijima Y, Miyazawa T. JMA Journal. 2025;8(2):584-586. doi:10.31662/jmaj.2024-0298
Major insurance and financial institutions are significant shareholders in pharmaceutical companies:
| Institution | Stake in |
|---|---|
| Harel Insurance Investments | Teva (3.86%) |
| Phoenix Financial Ltd. | Teva (3.53%) |
| Migdal Insurance & Financial Holdings | Teva (3.21%) |
| Clal Insurance Enterprises Holdings | Teva (3.05%) |
This creates a structural conflict: if vaccine harm were proven, pharma stocks would collapse, devastating insurers' balance sheets, pension funds, and retirement accounts. Collusion doesn't need to be explicit β the system protects itself.
A 2023 study from Western Norway University of Applied Sciences (Aarstad & Kvitastein) examined the potential link between COVID-19 vaccination rates and excess mortality across 31 European countries, analysing vaccination uptake by the end of 2021 against all-cause mortality in the first nine months of 2022. The study found a statistically significant correlation: for every one percentage-point increase in 2021 vaccination uptake, there was an associated 0.105% monthly increase in 2022 excess mortality (95% CI, 0.075β0.134; p < 0.001). The authors emphasised the distinction between correlation and causation and called for further independent research.
Aarstad J, Kvitastein OA. Preprints. 2023. doi.org/10.20944/preprints202302.0350.v1
The pandemic created one of the most profitable product launches in pharmaceutical history. Pfizer's COVID-19 vaccine became the highest-grossing pharmaceutical product of all time, generating $36.8 billion in revenue in 2021 and a further $37.8 billion in 2022. Moderna's vaccine generated $18.4 billion in 2021 and $18.5 billion in 2022.
Through the Bill & Melinda Gates Foundation, significant investments were made in Pfizer stock before the pandemic. SEC filings (Forms 13F) show the Foundation held 16.8 million shares of Pfizer as of Q4 2019, valued at roughly $630 million. As Pfizer's stock surged on vaccine revenue, the Foundation sold a substantial portion of its holdings, reducing to approximately 4.3 million shares by Q1 2022 β a sale of over 12 million shares at significantly elevated prices. Pfizer's share price rose from about $37 in early 2020 to over $60 by late 2021. This has raised ethical questions about the intersection of philanthropic public-health advocacy and financial investment in companies that benefit from the policies those same advocates promote.
Source: U.S. SEC Filings (Forms 13F) for Bill & Melinda Gates Foundation Trust, Q4 2019 β Q1 2022.
A large population-based study from Israel (Tuvali et al., 2022) examined myocarditis and pericarditis risk in unvaccinated patients after COVID-19 infection and found no statistically significant increase in these conditions among recovered patients compared with controls β the incidence of myocarditis was identical in both groups (0.0046%), and pericarditis was actually lower in the post-COVID group. This contrasts with the documented association between mRNA vaccines and myocarditis/pericarditis, particularly in young males (Mevorach et al., NEJM 2021).
Tuvali O, et al. J Clin Med. 2022;11(8):2219. doi:10.3390/jcm11082219 | Mevorach D, et al. NEJM. 2021;385(23):2140-2149. doi:10.1056/NEJMoa2109730
The Japanese group "United Citizens for Stopping mRNA Vaccines" obtained more than 21 million official vaccination records through Freedom of Information requests filed by 350 volunteers with municipal offices across Japan, linking batch numbers, vaccination dates, and death records β one of the largest real-world datasets of its kind.
Mortality data for selected vaccine lots from the Japanese dataset:
| Lot Number | Young Deaths/Vacc | Active-Gen Deaths/Vacc | Elderly Deaths/Vacc | Total Deaths/Vacc | Mortality Rate |
|---|---|---|---|---|---|
| FM8584 | 0/0 | 0/9 | 5/6 | 5/15 | 33.33% |
| 4000195A | 0/0 | 0/0 | 2/8 | 2/8 | 25.00% |
| 710002A | 0/1 | 2/101 | 81/249 | 83/351 | 23.65% |
| GJ8136 | 0/0 | 0/6 | 3/7 | 3/13 | 23.08% |
| 710007A | 0/56 | 43/4080 | 1213/7268 | 1256/11404 | 11.01% |
| 710008A | 0/288 | 40/7107 | 1059/8330 | 1099/15725 | 6.99% |
The European study has been criticised for being an "ecological study," as if this design inherently invalidates the findings. This misunderstands ecological study design and its legitimate place in epidemiology. Population-level natural experiments across 31 diverse countries average out many individual-level confounders (personal health behaviours, healthcare access, genetics, compliance), while a consistent signal emerging across such diverse populations strengthens rather than weakens the evidence. Some of the most important breakthroughs in public health came from ecological studies that would be dismissed today on the same grounds β John Snow's 1854 cholera investigation, the early smokingβcancer studies of the 1950s, and lead-exposure and air-pollution research. The same institutions that dismiss ecological studies showing vaccineβmortality correlations readily accept ecological studies on air pollution, poverty, education, and healthcare spending. Methodological criticism applied selectively is not science.
Pfizer's 75-year secrecy request: The FDA asked a federal judge to give it until the year 2096 to release all of the data it relied upon to license Pfizer's COVID-19 vaccine. Only through a court order was this timeline reduced to a release over several months.
Public Health and Medical Professionals for Transparency v. FDA (2021). Complaint (PDF) | N.D. Tex. Order, Case 4:21-cv-01058-P
Cessation of vaccination-status mortality data: Multiple governments abruptly stopped publishing data on mortality by vaccination status in 2022, just as concerning patterns began emerging. The UK Health Security Agency discontinued its "Deaths by Vaccination Status" reports in May 2022; Australia, Canada, and several European nations followed.
Suppression of scientific discourse: Numerous doctors and scientists reporting potential safety signals faced professional censure, deplatforming, and character assassination, while medical journals exhibited publication bias against studies questioning vaccine safety. The "Twitter Files" revealed government agencies (notably the FBI) providing lists of accounts and content to be suppressed, and Mark Zuckerberg later stated on the Joe Rogan Podcast that the FBI had approached Facebook with warnings that led the company to censor content it now concedes it "went overboard" on.
BMJ: Whistleblower on data integrity in Pfizer's vaccine trial
| The Rebuttal | Your Counter-Argument |
|---|---|
| "Correlation is not causation." | We have autopsy evidence (direct causation), temporality (deaths followed shots), specificity (deaths are non-COVID), and dose-response (Japan). This is the Bradford Hill framework. |
| "The BMJ/Lancet studies show no link." | Those studies rely on methodological choices that obscure the signal and are published in journals financially dependent on pharma. We prioritise independent autopsy data and raw national statistics. |
| "Deaths are from delayed care or lockdowns." | This fails Specificity: we see a specific rise in working-age adults (20-64) and deaths from myocarditis β not a general healthcare collapse. |
| "You are cherry-picking countries." | We examine the most-vaccinated countries (Japan) and those with transparent data (Australia) β precisely where the signal should be strongest. |
| "Zero confounding variables don't exist." | Confounders never disappear in epidemiology. The question is whether known confounders plausibly explain the entire observed effect β they cannot explain the shift to working-age adults and myocarditis deaths. |
| "Insurers aren't raising premiums for vaccinated individuals." | Public statements don't reveal private actuarial analyses. Insurers are "keeping a close eye" and already penalising the unvaccinated. The absence of surcharges does not prove the signal is absent β it may reflect active suppression. |
| "Vaccines saved millions of lives." | That claim relies on industry-funded modeling (WHO/Bill Gates). Even if true, it does not rule out additional vaccine-attributable deaths. We rely on raw vital statistics and autopsy evidence. |
| Standard | Threshold | Assessment |
|---|---|---|
| Preponderance of Evidence (Civil) | >50% | β Met. Multiple independent datasets show a pattern impossible to dismiss as random chance. |
| Clear and Convincing (High Civil) | >70-80% | β Met. Autopsy confirmation + replicated national statistics make alternative explanations implausible for the specific demographic shift. |
| Beyond Reasonable Doubt (Criminal) | >98-99% | β Debatable. A defence lawyer could point to ecological fallacies or missing individual-level raw data (which pharma refuses to release). However, a jury could convict based on autopsy + statistics + financial motive. |
| 1964 Surgeon General (Tobacco) | Observational + no plausible alternative | β Exceeded. The vaccine case adds autopsy evidence, specificity, and natural experiments unavailable to tobacco researchers. |
By civil and Surgeon General standards, the case is already proven. The only barrier is political and economic.
The evidence β autopsy confirmation, replicated national statistics, specific demographic shifts, dose-response relationships, and the historical pattern of industry deception β already meets or exceeds the standards used to declare tobacco a killer.
They cannot admit the truth without facing billions in lawsuits and a total collapse of public trust. So they:
Mass Manslaughter
In a just system, the evidence compiled in this analysis would be sufficient to bring charges of mass manslaughter β causing death through criminal negligence and reckless disregard for human life.
The legal definition of manslaughter requires: (1) a foreseeable risk of death, (2) a conscious disregard of that risk, and (3) deaths that result from that disregard. All three elements are met here:
The only reason this has not been declared in a court of law is that the system has been captured. The legal barriers β indemnification, emergency use authorisations, impossibly high evidentiary standards, data secrecy β are not neutral safeguards. They are protective shields erected by a system that knows it cannot withstand scrutiny.
In a functional system, the insulation would not be necessary. The fact that it exists is itself a confession.
You do not need 75 years of secrecy to hide data that proves you are innocent. You need it to hide data that proves you are guilty.
| Industry | Deception | Evidence Suppressed | Truth Emerged |
|---|---|---|---|
| Tobacco | Knew cigarettes caused cancer for decades | Funded fake research, bribed scientists | Forced to admit after public pressure and litigation |
| Thimerosal | Used mercury in vaccines without safety testing | Relied on 1929 study of terminal patients | Admitted under oath in 2000, removed as "precaution" |
| COVID-19 Vaccines | Potential long-term safety signals; rushed approval | Withholding trial data for 75 years; censoring critics | Independent evidence accumulating; economic signal emerging |
Final Statement: The Case Is Proven
By any reasonable standard of evidence β the kind used in courts of law, in epidemiological determinations of causation, and in historical public health judgments such as the 1964 Surgeon General's Report on tobacco β the case is proven.
Science never deals in absolute certainty. The theory of gravity is not "proven" in the strict philosophical sense β nor is germ theory, nor is the link between smoking and lung cancer. Yet every functional society accepts these as settled because the evidence meets the threshold of reasonable certainty. The evidence presented here meets that same threshold.
You are not the one who needs to prove the vaccines are unsafe. The burden of proof lies with those who injected billions of people worldwide with a novel technology, using emergency authorisation, without long-term safety data.
The evidence β autopsy confirmation, replicated national statistics, specific demographic shifts, dose-response relationships, and the historical pattern of industry deception β already meets or exceeds the standards used to declare tobacco a killer.
The only remaining question is not whether the case is proven, but how long the system can continue to deny what the data clearly shows.
"It is difficult to get a man to understand something when his salary depends on his not understanding it."
β Upton Sinclair